Clinical trial
A Phase II, Randomized, Observer-Blind,Multi-Center, Study to Evaluate Safety, Tolerability and Immunogenicity of an Adjuvanted Cell Culture-Derived H5N1 Subunit Influenza Virus Vaccine at Two Different Formulations in Healthy Adult Subjects.
NCT01776541 is registered in ClinicalTrials.gov with Novartis Vaccines as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase II, Randomized, Observer-Blind,Multi-Center, Study to Evaluate Safety, Tolerability and Immunogenicity of an Adjuvanted Cell Culture-Derived H5N1 Subunit Influenza Virus Vaccine at Two Different Formulations in Healthy Adult Subjects.
- Lead sponsor
- Novartis Vaccines
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- January 31, 2013
- Completion date
- May 31, 2014
- Enrollment
- 979 (actual)
- Sites
- 8
Conditions
As the registry lists them; a condition with its own page is linked.
pandemic h5n1 influenza